论文部分内容阅读
吡格列酮(Pioglitazon)是1种新型噻唑烷二酮类胰岛素增敏剂。本文报告作者关于吡格列酮对2型糖尿病伴发肥胖症患者的疗效进行研究的结果。对象与方法共选择20例2型糖尿病伴发肥胖症患者为研究对象。男4例,女16例;平均年龄55.5±1.21岁;糖尿病平均病程约4年。全部患者入院后均采
Pioglitazon is a novel thiazolidinedione insulin sensitizer. This article reports the authors’ findings regarding the efficacy of pioglitazone in patients with type 2 diabetes and obesity. Subjects and Methods A total of 20 patients with type 2 diabetes mellitus and obesity were selected as the study subjects. 4 males and 16 females with an average age of 55.5 ± 1.21 years and an average duration of diabetes of 4 years. All patients were admitted after admission